PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Aug 26, 2013
SOUTH PLAINFIELD, NJ – August 26, 2013 – Data published in the medical journal Muscle & Nerve demonstrate the clinical meaningfulness of the 6-minute walk test (6MWT) as a primary endpoint to measure disease progression and walking ability in ambulatory Duchenne muscular dystrophy (DMD) trials. The research also showed that a range of 20 ...
Aug 12, 2013
SOUTH PLAINFIELD, NJ - August 12, 2013 - PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced financial and corporate results for the quarter ended June 30, 2...
Aug 8, 2013
SOUTH PLAINFIELD, NJ – August 8, 2013 – PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from Roche. "We are excited about thi...
Aug 6, 2013
SOUTH PLAINFIELD, NJ – August 6, 2013 –PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer of PTC Therapeutics will present a company overview at the Wedbush Securities Life Sciences Management Access Conference in New York City on Tuesday, August 13, 2013 at 1:20 pm EST. In addition, Dr. Stuar...
Aug 5, 2013
SOUTH PLAINFIELD, NJ – August 5, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will report financial results for the second quarter ended June 30, 2013 following the close of market on Monday, August 12, 2013. PTC management will host a conference call and webcast to discuss financial results and provide ...
Jun 25, 2013
SOUTH PLAINFIELD, NJ – June 25, 2013 – PTC Therapeutics, Inc. (PTC) (NASDAQ: PTCT) today announced the closing of its initial public offering of 9,627,800 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts, including 1,255,800 shares of common stock issued upon the exercise in full by the ...
Jun 20, 2013
SOUTH PLAINFIELD, NJ – June 20, 2013 – PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an o...
Jun 3, 2013
SOUTH PLAINFIELD, NJ – June 3, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Kovacs will be responsible for all finance-related activities at PTC."We are excited to welcome Shane as a member of ou...
May 16, 2013
South Plainfield, NJ—May 16, 2013—PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not bee...
Apr 23, 2013
SOUTH PLAINFIELD, NJ – April 23, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Rothera will be responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug...
Page: FirstPrevious ...
21
NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue